At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in earlier stages of development. It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances,...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of leukocyte biology Ročník 94; číslo 1; s. 41 - 53
Hlavní autoři:	Callahan, Margaret K., Wolchok, Jedd D.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Society for Leukocyte Biology 01.07.2013
Témata:	Antibodies, Blocking - therapeutic use Clinical Trials as Topic CTLA-4 Antigen - antagonists & inhibitors CTLA-4 Antigen - immunology endpoints Humans Immunotherapy Neoplasms - immunology Neoplasms - therapy overall survival Paired Basic-Translational Reviews Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology tumor overall survival endpoints tumor
ISSN:	0741-5400, 1938-3673, 1938-3673
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in earlier stages of development. It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumors. The modulation of signaling via coinhibitory or costimulatory receptors expressed on T cells has proven to be a potent way to amplify antitumor immune responses. This approach has been exploited successfully for the generation of a new class of anticancer therapies, “checkpoint‐blocking” antibodies, exemplified by the recently FDA‐approved agent, ipilimumab, an antibody that blocks the coinhibitory receptor CTLA‐4. Capitalizing on the success of ipilimumab, agents that target a second coinhibitory receptor, PD‐1, or its ligand, PD‐L1, are in clinical development. Lessons learned from treating patients with CTLA‐4 and PD‐1 pathway‐blocking antibodies will be reviewed, with a focus on concepts likely to inform the clinical development and application of agents in earlier stages of development. See related review At the bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
ISSN:	0741-5400 1938-3673 1938-3673
DOI:	10.1189/jlb.1212631